Matthew Biegler
Stock Analyst at Oppenheimer
(0.88)
# 3,650
Out of 4,778 analysts
80
Total ratings
24.29%
Success rate
-17.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $0.85 | +844.18% | 7 | Mar 21, 2025 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 → $25 | $4.20 | +495.95% | 5 | Mar 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $8.13 | +453.51% | 4 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $107.88 | +6.60% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $18.03 | +193.95% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $10.32 | +219.77% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $1.87 | +972.39% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $2.97 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $6.75 | +122.22% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $1.59 | +591.82% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $93.15 | +34.19% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $15.92 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $3.12 | +349.44% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.37 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $0.90 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.28 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,500 → $450 | $3.29 | +13,577.81% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.40 | +362.96% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.44 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.12 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $4.15 | +8,574.70% | 1 | Nov 30, 2022 |
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.85
Upside: +844.18%
Olema Pharmaceuticals
Mar 19, 2025
Reiterates: Outperform
Price Target: $30 → $25
Current: $4.20
Upside: +495.95%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $8.13
Upside: +453.51%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $107.88
Upside: +6.60%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $18.03
Upside: +193.95%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.32
Upside: +219.77%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.87
Upside: +972.39%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.97
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $6.75
Upside: +122.22%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $1.59
Upside: +591.82%
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $93.15
Upside: +34.19%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $15.92
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $3.12
Upside: +349.44%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.37
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $0.90
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.28
Upside: -
Aug 11, 2023
Maintains: Outperform
Price Target: $1,500 → $450
Current: $3.29
Upside: +13,577.81%
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $5.40
Upside: +362.96%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.44
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.12
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $4.15
Upside: +8,574.70%